查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438063

2030 年促紅血球生成素藥物市場預測：按類型、產品、分銷管道、應用、最終用戶和地區進行的全球分析

Erythropoietin Drugs Market Forecasts to 2030 - Global Analysis By Type (Biosimilars and Biologics), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Products), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球促紅血球生成素藥物市場規模將達107億美元，預計2030年將達到256億美元，預測期內年複合成長率為13.2%。

促紅血球生成素製劑是一類包含促紅血球生成素（腎臟天然產生的荷爾蒙）重組製劑的藥物。這些藥物目的是刺激和增加紅血球合成，可有效控制與貧血相關的症狀。促紅血球生成素製劑可透過增加紅血球數量來治療虛弱、呼吸困難和頭暈等貧血症狀，改善患者的日常功能。

根據世界衛生組織（WHO）的資料，全球 42%的 5 歲以下兒童和 40%的孕婦患有貧血。

貧血增加

貧血是一種以紅血球數量減少或血紅素數量減少為特徵的疾病，導致血液攜氧能力下降。 EPO 製劑透過促進紅血球的產生，在貧血治療中發揮重要作用。此外，癌症患者通常會使用 EPO 製劑來控制化療引起的貧血並提高生活品質。這些疾病的日益普及導致貧血的整體負擔增加，推動了對 EPO 製劑的需求。

可能的副作用

促紅血球生成素藥物市場面臨一個潛在的限制因素：與藥物使用相關的副作用的發生。主要關注點之一是與服用促紅血球生成素製劑相關的心血管事件風險，例如血栓症和高血壓。此外，另一個潛在的副作用是發生純紅血球再生不良性貧血（PRCA），這是一種罕見但嚴重的疾病，其特徵是紅血球產生突然停止。

提高醫療保健意識

醫療保健意識的提高是促紅血球生成素製劑市場的關鍵促進因素。隨著患者和醫療保健專業人員對包括貧血在內的健康狀況的認知不斷提高，人們越來越認知到促紅血球生成素製劑在治療貧血相關併發症中的重要性。此外，越來越多的患者尋求及時有效的治療，其中促紅血球生成素製劑發揮重要作用，例如慢性腎臟病。這些因素推動市場需求。

新的替代藥物

隨著科學和醫學研究的進展，新的治療選擇，包括非藥物干預和替代藥物療法越來越受到關注，挑戰促紅血球生成素製劑的優越性。此外，市場上生物相似藥的供應和採用的增加可能會導致定價壓力和市場佔有率競爭，影響品牌促紅血球生成素產品的收益。

COVID-19 的影響

由於COVID-19大流行，促紅血球生成素製劑市場受到了重大影響。非緊急醫療程序和治療，包括治療貧血的促紅血球生成素產品，被推遲或延遲，影響了整體市場需求。此外，藥品供應鏈的中斷、旅行限制和勞動力短缺阻礙了促紅血球生成素產品的生產和分銷。

腫瘤學領域預計在預測期內規模最大

預計癌症領域將佔據最大佔有率。癌症患者常因疾病本身或化療的副作用而出現貧血。促紅血球生成素製劑，例如阿法紅血球生成素，透過刺激紅血球的產生來治療癌症患者的貧血。此外，促紅血球生成素治療可改善患者健康，並可透過維持足夠的攜氧紅血球來實現更有效的癌症治療。

生物製藥產業預計在預測期內年複合成長率最高。

預計生技藥品領域將在預測期內出現良好的成長。生技藥品目的是模仿促紅血球生成素刺激骨髓中紅血球生成的天然能力。促紅血球生成素生物製藥通常用於治療與慢性腎臟病、癌症化療和某些其他醫療狀況相關的貧血。此外，生物製藥，包括基於促紅血球生成素的藥物，透過為貧血提供有針對性的有效治療，為患者的治療做出了重大貢獻。

佔有率最大的地區

由於強大的醫療基礎設施、技術創新和高普及率，北美在估計期間佔據了最大的市場佔有率。貧血的流行，特別是在接受透析的 CKD 患者和接受癌症治療的患者中，推動北美對促紅血球生成素產品的需求。此外，該地區也處於生物技術和藥物研究的前沿，支持促紅血球生成素配方開發的持續創新。

年複合成長率最高的地區：

亞太地區預計將在預測期內實現有益成長，因為它對全球製藥業做出了重大貢獻。中國和印度等國家已成為促紅血球生成素製劑生產和消費的主要參與者。該地區的製藥業經歷高度的研發活動，推動創新並推出新的 EPO 配方。此外，亞太地區不斷發展的醫療基礎設施和不斷增加的醫療費用也促進了促紅血球生成素製劑市場的成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間存在敵對關係

第5章 全球促紅血球生成素製劑市場：依類型

  • 生物相似藥
  • 生技藥品

第6章 全球促紅血球生成素製劑市場：依產品

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • 其他產品

第7章 全球促紅血球生成素藥品市場：依通路分類

  • 網路藥房
  • 醫院藥房
  • 其他分銷管道

第8章 全球促紅血球生成素製劑市場：依應用分類

  • 血液學
  • 癌症
  • 神經病學
  • 腎臟疾病
  • 其他用途

第9章 全球促紅血球生成素製劑市場：依最終用戶分類

  • 專科診所
  • 醫院
  • 其他最終用戶

第10章 全球促紅血球生成素製劑市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • Amgen, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc
  • LG Chem
  • F. Hoffmann-La Roche Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Ranbaxy Laboratories
  • Roche Diagnostics
Product Code: SMRC25051

According to Stratistics MRC, the Global Erythropoietin Drugs Market is accounted for $10.7 billion in 2023 and is expected to reach $25.6 billion by 2030 growing at a CAGR of 13.2% during the forecast period. Erythropoietin drugs are a class of medications that include recombinant forms of erythropoietin, a hormone produced naturally in the kidneys. These drugs are designed to stimulate and increase the synthesis of red blood cells, making them effective in managing conditions associated with anaemia. Erythropoietin medications treat anaemia symptoms such as weakness, dyspnea, and vertigo by raising red blood cell counts, leading to improved daily functioning for patients.

According to the World Health Organization (WHO), 42% of children under the age of five and 40% of pregnant women worldwide are anemic.

Market Dynamics:

Driver:

Rising prevalence of anaemia

Anaemia is a condition characterized by a decrease in the number of red blood cells or a decrease in the amount of haemoglobin, leading to reduced oxygen-carrying capacity in the blood. EPO drugs play a crucial role in managing anaemia by stimulating the production of red blood cells. Moreover, EPO drugs are often prescribed to cancer patients to manage chemotherapy-induced anaemia and improve their quality of life. The increasing prevalence of these conditions contributes to the overall burden of anaemia in the population, thereby driving the demand for EPO drugs.

Restraint:

Potential adverse effects

The erythropoietin drug market faces potential restraints linked to the occurrence of adverse effects associated with the therapeutic use of these drugs. One significant concern is the risk of cardiovascular events, including thrombosis and hypertension, associated with the administration of erythropoietin drugs. Furthermore, another potential adverse effect is the development of pure red cell aplasia (PRCA), a rare but serious condition characterized by a sudden halt in the production of red blood cells.

Opportunity:

Increased healthcare awareness

Increased healthcare awareness serves as a pivotal driver in the erythropoietin drugs market. As awareness about health conditions, including anemia, continues to rise among patients and healthcare professionals, there is a heightened recognition of the significance of erythropoietin drugs in managing anemia-associated complications. Moreover, patients are increasingly seeking timely and effective treatments for conditions like chronic kidney disease and other disorders where erythropoietin drugs play a vital role. These factors drive market demand.

Threat:

Emerging alternatives

As scientific and medical research progresses, new therapeutic options, including non-pharmacological interventions and alternative drug therapies, are gaining attention and posing a challenge to the dominance of erythropoietin drugs. Moreover, the increasing availability and adoption of biosimilars in the market can lead to pricing pressures and market share competition, impacting the revenue of branded erythropoietin drugs.

Covid-19 Impact

The erythropoietin drug market experienced notable impacts from the COVID-19 pandemic. Non-urgent medical procedures and treatments, including those involving erythropoietin drugs for anaemia, were deferred or delayed, affecting the overall market demand. Additionally, disruptions in the pharmaceutical supply chain, restrictions on movement, and workforce shortages posed obstacles to the production and distribution of erythropoietin drugs.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to hold the largest share. Cancer patients frequently experience anaemia due to the effects of the disease itself or as a side effect of chemotherapy. Erythropoietin drugs, such as epoetin-alfa, are employed to address anaemia in cancer patients by stimulating the production of red blood cells. Moreover, erythropoietin therapies improve the patient's well-being, potentially allowing for more effective cancer treatment by maintaining adequate levels of oxygen-carrying red blood cells.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics are designed to mimic the natural function of erythropoietin in stimulating the production of red blood cells in the bone marrow. Erythropoietin biologics are commonly used to address anaemia associated with chronic kidney disease, cancer chemotherapy, and certain other medical conditions. Additionally, biologics, including erythropoietin-based agents, contribute significantly to patient care by offering targeted and effective treatments for anaemia.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, technological innovation, and a high prevalence of conditions. The prevalence of anaemia, particularly in CKD patients undergoing dialysis and individuals undergoing cancer treatments, has fuelled the demand for erythropoietin drugs in North America. Moreover, the region is also at the forefront of biotechnological and pharmaceutical research, driving continuous innovation in erythropoietin drug development.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, owing to its significant contribution to the global pharmaceutical industry. Countries like China and India have emerged as key players in the production and consumption of erythropoietin drugs. The region's pharmaceutical sector benefits from robust research and development activities, fostering innovation and the introduction of new EPO formulations. Additionally, the Asia-Pacific's evolving healthcare infrastructure and increasing healthcare expenditure contribute to the growth of the erythropoietin drug market.

Key players in the market

Some of the key players in the Erythropoietin Drugs Market include Johnson & Johnson Services, Inc., AstraZeneca, Amgen, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc, LG Chem, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories and Roche Diagnostics.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In September 2023, Sun Pharmaceutical Industries Limited announced that it had entered into a licence agreement with American biopharmaceutical company Pharmazz Inc to commercialise an innovative drug, Tyvalzi (Sovateltide) in India.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In October 2020, Novartis and Molecular Partners AG announced collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.

Types Covered:

  • Biosimilars
  • Biologics

Products Covered:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Other Products

Distribution Channels Covered:

  • Online Pharmacy
  • Hospital Pharmacy
  • Other Distribution Channels

Applications Covered:

  • Hematology
  • Cancer
  • Neurology
  • Renal Diseases
  • Other Applications

End Users Covered:

  • Speciality Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Erythropoietin Drugs Market, By Type

  • 5.1 Introduction
  • 5.2 Biosimilars
  • 5.3 Biologics

6 Global Erythropoietin Drugs Market, By Product

  • 6.1 Introduction
  • 6.2 Epoetin-alfa
  • 6.3 Epoetin-beta
  • 6.4 Darbepoetin-alfa
  • 6.5 Other Products

7 Global Erythropoietin Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Online Pharmacy
  • 7.3 Hospital Pharmacy
  • 7.4 Other Distribution Channels

8 Global Erythropoietin Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Hematology
  • 8.3 Cancer
  • 8.4 Neurology
  • 8.5 Renal Diseases
  • 8.6 Other Applications

9 Global Erythropoietin Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Speciality Clinics
  • 9.3 Hospitals
  • 9.4 Other End Users

10 Global Erythropoietin Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Johnson & Johnson Services, Inc.
  • 12.2 AstraZeneca
  • 12.3 Amgen, Inc.
  • 12.4 Novartis AG
  • 12.5 Teva Pharmaceutical Industries Ltd.
  • 12.6 Pfizer Inc
  • 12.7 LG Chem
  • 12.8 F. Hoffmann-La Roche Ltd.
  • 12.9 Sun Pharmaceutical Industries Ltd.
  • 12.10 Intas Pharmaceuticals Ltd.
  • 12.11 Dr. Reddy's Laboratories Ltd
  • 12.12 Ranbaxy Laboratories
  • 12.13 Roche Diagnostics

List of Tables

  • Table 1 Global Erythropoietin Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 4 Global Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 5 Global Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 6 Global Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 7 Global Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 8 Global Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 9 Global Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 10 Global Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 11 Global Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 12 Global Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 13 Global Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 14 Global Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 15 Global Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 16 Global Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 17 Global Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 18 Global Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 19 Global Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 20 Global Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 22 Global Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 27 North America Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 28 North America Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 29 North America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 30 North America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 31 North America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 32 North America Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 North America Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 34 North America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 35 North America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 36 North America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 37 North America Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 38 North America Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 39 North America Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 40 North America Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 41 North America Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 42 North America Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 North America Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 North America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 45 North America Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 50 Europe Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 51 Europe Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 52 Europe Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 53 Europe Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 54 Europe Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 55 Europe Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 56 Europe Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 57 Europe Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 58 Europe Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 59 Europe Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 60 Europe Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 62 Europe Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 63 Europe Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 64 Europe Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 65 Europe Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 66 Europe Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 67 Europe Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 68 Europe Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 Europe Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 73 Asia Pacific Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 74 Asia Pacific Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 75 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 76 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 77 Asia Pacific Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 78 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 79 Asia Pacific Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 80 Asia Pacific Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 81 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 82 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 83 Asia Pacific Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 84 Asia Pacific Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 85 Asia Pacific Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 86 Asia Pacific Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 87 Asia Pacific Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 88 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 89 Asia Pacific Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 90 Asia Pacific Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 91 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 92 Asia Pacific Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 96 South America Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 97 South America Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 South America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 99 South America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 100 South America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 101 South America Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 102 South America Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 103 South America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 104 South America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 105 South America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 106 South America Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 107 South America Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 108 South America Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 109 South America Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 110 South America Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 111 South America Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 112 South America Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 113 South America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 114 South America Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 115 South America Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 119 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 120 Middle East & Africa Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 121 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 122 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 123 Middle East & Africa Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 124 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 125 Middle East & Africa Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 126 Middle East & Africa Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 127 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 128 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 129 Middle East & Africa Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 130 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 131 Middle East & Africa Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 132 Middle East & Africa Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 133 Middle East & Africa Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 134 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 135 Middle East & Africa Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 136 Middle East & Africa Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 137 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 138 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)